Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Dussel

Vascular Surgery Wilsonville, OR Medical Doctor

NPI 1902192396 CMS profile 2787164

25030 Sw Parkway Ave Ste 200, Wilsonville, OR 97070

Open in the dashboard

General payments

$19,901

240 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Dussel of Wilsonville, OR is reported in the CMS Open Payments database as having received $19,901 across 240 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,244 45
2024 General $10,496 94
2023 General $2,735 30
2022 General $1,695 34
2021 General $1,618 17
2020 General $222 3
2019 General $892 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Dussel
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to John Dussel were reported at $2,244. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year John Dussel Vascular Surgery median Middle half National median
2019 $892 $796 $226–$2,363 $163
2020 $222 $348 $118–$1,110 $114
2021 $1,618 $471 $158–$1,421 $132
2022 $1,695 $725 $222–$2,183 $149
2023 $2,735 $836 $257–$2,440 $160
2024 $10,496 $909 $252–$2,619 $164
2025 $2,244 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $6,124 25 payments
  2. Medtronic, Inc. $3,783 52 payments
  3. Silk Road Medical, Inc. $2,501 33 payments
  4. Boston Scientific Corporation $1,858 47 payments
  5. Medical Device Business Services, Inc. $1,324 3 payments
  6. Bard Peripheral Vascular, Inc. $946 21 payments
  7. Medtronic Vascular, Inc. $590 8 payments
  8. W. L. Gore & Associates, Inc. $413 8 payments
  9. Cardiovascular Systems Inc. $337 3 payments
  10. Shockwave Medical, Inc $319 12 payments
  11. Other $1,708 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,039 215 payments
  2. Travel and Lodging $6,462 24 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,400 1 payment
Products named General payments · program years 2019–2025
  1. Indigo System $2,990 14 payments
  2. RUBY Coil $2,724 6 payments
  3. ENROUTE Transcarotid Stent $2,339 31 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $2,339 31 payments
  5. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $2,151 23 payments
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $2,151 23 payments
  7. TurboHawk $1,592 11 payments
  8. SYNFIX Evolution $1,344 4 payments
  9. HawkOne $791 23 payments
  10. ENDURANT IIS $448 7 payments
  11. Other $8,380 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

79

Median for Vascular Surgery: 122

Drug cost

$727

Median for Vascular Surgery: $14,135

Branded share of claims

64.6%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 51 $596
Oxycodone Hcl Generic 28 $131

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$295,301

Of which drugs: $335

Medicare patients

222

Average age 73

Services billed

1,855

105 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 51%
Diabetes 46%
Ischemic heart disease 44%
Arthritis 43%
Heart failure 34%
Atrial fibrillation 31%
Depression 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 13 1,150 $335

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record